Aim: Post-hoc analysis of the efficacy and safety of ertugliflozin in East/Southeast (E/SE) Asian patients with type 2 diabetes mellitus (T2DM).
| INTRODUCTION
The worldwide prevalence of diabetes in adults (aged 20-79 years) is expected to increase from 8.8% (~425 million people) in 2015 to an estimated 9.9% (~629 million people) by 2045. 1 In Asian populations, including East Asia, the rate of diabetes has increased significantly over the past decade 2 ; this may be related to increasing urbanization, a decrease in physical activity and a rise in obesity. [2] [3] [4] East Asian patients with type 2 diabetes mellitus (T2DM) generally have a lower body mass index (BMI) compared with patients from other regions. [4] [5] [6] Genetic factors vary between populations; there are significant differences between East Asian and European populations in the frequency of risk alleles associated with the development of T2DM. 4 Environmental and lifestyle risk factors also have an impact on the development and management of T2DM. For example, white rice is an important part of the daily diet in East Asians and its consumption is associated with the risk of T2DM. 6 As such, it is important to undertake an assessment of the efficacy and safety of antihyperglycaemic therapy in East Asian patients with T2DM.
Ertugliflozin, a selective sodium-glucose cotransporter 2 (SGLT2)
inhibitor, 7, 8 has been evaluated for the treatment of adults with T2DM in the phase 3 VERTIS (eValuation of ERTugliflozin effIcacy and Safety) clinical trial programme. [9] [10] [11] [12] [13] [14] [15] The results led to the approval of ertugliflozin as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM, including in Hong Kong, Korea, Taiwan and several other East Asian countries.
This post-hoc analysis of the phase 3 VERTIS programme included data from multinational studies that enrolled patients from East Asia and other regions. The safety and efficacy of ertugliflozin 5 mg and 15 mg were evaluated in East and Southeast (E/SE) Asian patients with T2DM. Non-E/SE Asian patients were also analyzed for completeness.
| MATERIALS AND METHODS

| Study design: data sources
Three phase 3 VERTIS studies were included in the efficacy assessments ( Figure 1 ). Two similarly designed placebo-controlled 26-week studies, VERTIS MET 14 (ertugliflozin add-on to metformin) and VERTIS SITA2 9 (ertugliflozin add-on to metformin and sitagliptin), were pooled as the "placebo pool". Data from VERTIS SU, 11 a 52-week active-comparator study that compared ertugliflozin with glimepiride as add-on to metformin, were analysed separately. Two other studies, VERTIS FACTORIAL 13 and VERTIS RENAL, 10 also enrolled patients from E/SE Asian countries, but they were not included in the efficacy analysis because of the relatively small numbers of E/SE Asian patients (<20 per treatment arm) and because the study designs were not appropriate for pooling data for analysis of ertugliflozin efficacy (ertugliflozin was co-administered with sitagliptin in the VERTIS FACTORIAL study and VERTIS RENAL enrolled patients with chronic kidney disease). However, the safety data from these two studies were included in the safety analysis to provide a robust population appropriate for safety assessment.
Safety analyses, except those related to documented and severe hypoglycaemia and estimated glomerular filtration rate (eGFR), were performed in the "broad pool", which includes data from seven placebo- 
Number of E/SE Asian patients n = 0 n = 69 n = 92 n = 174 n = 0 n = 81 n = 39 were assessed in the placebo pool only to avoid the confounding effects of the sulphonylurea glimepiride in the broad pool upon the analysis.
| Patient population and treatments
The E/SE Asian population was defined as patients enrolled from
Hong Kong, Korea, Malaysia, Philippines, Taiwan and Thailand. The placebo pool included 161 E/SE Asian patients and the activecomparator study included 174 E/SE Asian patients. Data are also presented for the non-E/SE Asian population for completeness. The non-E/SE Asian population comprised patients enrolled from other countries. Details of inclusion criteria, exclusion criteria and the study design for the individual studies have been reported previously. 9, 11, 14 Adult patients (aged ≥18 years) with T2DM according to American Diabetes Association criteria with baseline HbA1c levels of 7.0%-10.5%
(range depending on the study) were randomized 1:1:1 to nonertugliflozin (placebo or glimepiride), ertugliflozin 5 mg or ertugliflozin 15 mg once daily in addition to existing metformin or metformin plus sitagliptin therapy ( Figure 1) . 9, 11, 14 Background antihyperglycaemic agents other than protocol-specified background therapy were stopped at the screening visit. Glycaemic rescue therapy was prescribed for patients who exceeded protocol-specified glycaemic thresholds. 9, 11, 14 All studies were conducted in accordance with the principles of Good Clinical Practice and were approved by the appropriate institutional review boards and regulatory agencies. Informed consent was obtained from all of the individuals in each study.
| Efficacy endpoints and assessments
Efficacy endpoints were change from baseline to week 26 or week 52 in HbA1c, fasting plasma glucose (FPG), body weight and systolic blood pressure (SBP). The proportion of patients with HbA1c <7.0% at week 26 or week 52 was also evaluated. Body weight was measured in duplicate using a standardized digital scale. Sitting blood pressure was measured in triplicate with an automated oscillometric blood pressure measuring device.
| Safety endpoints
Safety endpoints included incidences of adverse event (AE) summary measures (including incidence of AEs and serious AEs) and prespecified
AEs of interest for SGLT2 inhibitors: genital mycotic infection (GMI) (by gender), urinary tract infection, volume depletion and documented and severe hypoglycaemia.
| Statistical methods
The full analysis set (FAS) population consisted of all randomized patients who received at least one dose of study medication and had at least one measurement for the analysis endpoint (baseline or postrandomization). Change from baseline in efficacy endpoints was analysed in the FAS population separately for each subgroup using a constrained longitudinal data analysis model to estimate least square (LS) mean changes. 16 Analysis of the placebo pool used fixed effects Safety analyses were based on the all subjects as treated (ASaT) population, consisting of all randomized patients who received at least one dose of study medication. Safety data obtained after initiation of glycaemic rescue therapy were not censored (including rescue approach), except for hypoglycaemia data, which were assessed using the excluding rescue approach to avoid confounding the results by use of rescue medication.
Demographic and baseline disease characteristics were summarized descriptively in the ASaT population.
3 | RESULTS
| Patient disposition and baseline characteristics
The placebo pool comprised 161 E/SE Asian patients (placebo 55 (100) 51 (100) 56 (100) 54 (100) 64 (100) 135 (100) 155 (100) 165 ( 55 (100) 51 (100) 56 (100) 54 (100) 64 (100) 128 ( At screening for the placebo pool and active comparator study or at randomization for the broad pool.
b
One patient was reported in the category of "not on an AHA" at screening; however, this patient was taking metformin at screening.
across treatment groups in both the E/SE Asian population (Table 1) and the non-E/SE Asian population (Table S1) . The E/SE Asian population had a lower mean body weight, BMI and FPG compared with the non-E/SE Asian population.
| Glycaemic control
In the E/SE Asian population, ertugliflozin provided a greater reduc- 
| Safety
In the ertugliflozin groups, there were no notable differences in the incidences of AEs, serious AEs or AEs leading to discontinuation of study medication compared with the non-ertugliflozin group in both populations ( Table 2 ). There was one death (acute myocardial infarction) in the E/SE Asian population in the ertugliflozin 5 mg group, and a low incidence of death across groups in the non-E/SE Asian population.
GMI AEs were reported in males and females with ertugliflozin but not with non-ertugliflozin in the E/SE Asian population. In the non-E/ SE Asian population, the incidence of GMI in males and females was higher with ertugliflozin compared with non-ertugliflozin ( Table 2 ).
In the placebo pool, few patients in the E/SE Asian population had documented hypoglycaemia and the incidence with ertugliflozin in the E/SE Asian population was not notably different from the non-E/SE Asian population. Of the six patients in the E/SE Asian population with documented hypoglycaemia (four in the ertugliflozin 5 mg group and two in the ertugliflozin 15 mg group), precipitating factors were identified in five of the patients, including skipped meals or increases in physical activity. There were no episodes of severe hypoglycaemia in the E/SE Asian population. The incidence of documented and severe hypoglycaemia was low across treatment groups in the non-E/SE Asian population (Table 2 ).
In both the placebo pool and the active-controlled study, a small early transient decrease in eGFR was observed with ertugliflozin respectively, and at week 26 it was 3.3 (11.1), 3.1 (11.2) and 0.7 (9.5) mL/min/1.73m 2 , respectively. In the active-controlled study, the mean T A greater reduction from baseline in SBP was observed with ertugliflozin treatment compared with placebo and glimepiride in the E/SE Asian population. The SBP lowering may be of particular relevance in East Asia, given the high burden of stroke in this region. 21, 22 The ongoing VERTIS CV trial, which enrolled 522 (6%) patients from Asia, will evaluate the impact of ertugliflozin on cardiovascular outcomes in patients with T2DM. 23 Overall, the efficacy of ertugliflozin in the E/SE Asian and non-E/ SE Asian populations was generally consistent with results for the total cohorts for the placebo pool 18 and the active-comparator study, 11 as well as with the overall population of patients with T2DM
in the phase 3 VERTIS programme 9, [11] [12] [13] [14] [15] Both doses of ertugliflozin were generally well tolerated among E/SE Asian and non-E/SE Asian patients with T2DM. In the non-E/SE Asian population, there was a higher incidence of male and female GMI with ertugliflozin compared with non-ertugliflozin; however, a lower incidence was observed across all treatment groups in the E/SE Asian population and data were insufficient to draw conclusions. It is not anticipated that there would be a difference in the risk of GMIs in E/SE Asian patients receiving SGLT2 inhibitors relative to other ethnic populations. A possible explanation for the lower incidence in E/SE Asians compared with non-E/SE Asians may be that it is in part a result of cultural reporting bias, which was proposed as a possible explanation for similar findings in a study with canagliflozin in Asian patients with T2DM. 20 A recent meta-analysis of East Asian patients also reported a higher incidence of genital tract infections in those receiving SGLT2 inhibitors compared with the control treatment arms (placebo or non-SGLT2 inhibitor antihyperglycaemic drugs). 24 Few patients in the E/SE Asian population had documented hypoglycaemia. In the E/SE Asian population, the incidence of hypoglycaemia in the ertugliflozin groups was similar to that observed in the non-E/SE Asian population, and the lower incidence observed in the placebo group for the E/SE Asian population compared with the non-E/SE Asian population should be interpreted with caution given the small numbers of patients. There were no reports of severe hypoglycaemia in the E/SE Asian population. The observed safety profile is consistent with the overall safety data that have been published for ertugliflozin to date. 9, [11] [12] [13] [14] [15] 25 East/SE Asian patients included in the current analysis of ertugliflozin efficacy had normal baseline renal function with a baseline eGFR similar to studies of other SGLT2 inhibitors in Asian and E/SE Asian populations (85.9 to 95.3 mL/min/m 2 ). 19, 20 A small initial decrease from baseline in eGFR was observed with ertugliflozin in the E/SE Asian population in the placebo pool and active-comparator study that returned to baseline over time. These results are consistent with findings from other studies in the VERTIS phase 3 programme and this pattern of eGFR change from baseline is common among SGLT2 inhibitors.
The safety and tolerability of another SGLT2 inhibitor, empagliflozin, in East Asian patients with T2DM are reported in a pooled analysis based on >2100 patient-years' exposure. 19 Empagliflozin was generally well tolerated in this population with a similar safety profile in terms of general AEs and prespecifed AEs to those described here with ertugliflozin. Incidences of hypoglycaemia differed according to baseline antihyperglycaemic medication, with a higher risk in patients on background sulphonylurea therapy as expected because of the associated stimulation of insulin secretion. 26 Similar to the observations in our analysis, the overall rate of genital infections was lower in East Asian trial participants compared with the overall analysis population, irrespective of gender.
In conclusion, treatment with ertugliflozin 5 mg and 15 mg was associated with clinically meaningful reductions in HbA1c, FPG, body weight and SBP, and was generally well tolerated in patients with
T2DM from E/SE Asian countries. 
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